Igor Astsaturov, MD, PhD, discusses the planned phase 1 trial of LP-184 in multiple advanced solid tumors and central nervous system cancers, including pancreatic cancer.
Igor Astsaturov, MD, PhD
Advertisement
Igor Astsaturov, MD, PhD, is an associate professor in the department of hematology/oncology and co-director of The Marvin and Concetta Greenberg Pancreatic Cancer Institute at Fox Chase Cancer Center in Philadelphia, PA.
Articles by Igor Astsaturov, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
